Mp70-11 Racial Disparities in Radiation Treatment Modality for Prostate Cancer

You have accessJournal of UrologyDiversity, Equity & Inclusion: Health Equity & Outcomes III (MP70)1 May 2024MP70-11 RACIAL DISPARITIES IN RADIATION TREATMENT MODALITY FOR PROSTATE CANCER Mitchell B. Alameddine, Shan Wu, Oluwaseun Orikogbo, Danielle Sharbaugh, Jonathon Yabes, Daisy Obiora, Michael G. Stencel, Benjamin J. Davies, Lindsay Sabik, and Bruce L. Jacobs Mitchell B. AlameddineMitchell B. Alameddine , Shan WuShan Wu , Oluwaseun OrikogboOluwaseun Orikogbo , Danielle SharbaughDanielle Sharbaugh , Jonathon YabesJonathon Yabes , Daisy ObioraDaisy Obiora , Michael G. StencelMichael G. Stencel , Benjamin J. DaviesBenjamin J. Davies , Lindsay SabikLindsay Sabik , and Bruce L. JacobsBruce L. Jacobs View All Author Informationhttps://doi.org/10.1097/01.JU.0001008796.84999.75.11AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Stereotactic Body Radiation Therapy (SBRT) and Intensity Modulated Radiation Therapy (IMRT) are two common radiation treatment options used for prostate cancer therapy. SBRT has increased in use over the past decade, owing to its decreased number of treatment sessions and patient convenience. Factors associated with the uptake of this relatively novel therapy in prostate cancer patients are poorly understood. Thus, we attempted to characterize choice of radiation therapy by race to help elucidate factors contributing to different treatment decisions. METHODS: We studied 2,232 prostate cancer patients diagnosed between 2008-2017 in the SEER-Medicare dataset who were treated with SBRT or IMRT at physician practices (i.e. networks) offering SBRT. Our analysis focused on white or black patients with clinically localized prostate cancer. We analyzed patient demographics and compared median times from diagnosis to treatment using the Wilcoxon rank-sum test. RESULTS: Black patients were more likely than white patients to receive IMRT (82% vs 67%) and less likely to receive SBRT than white patients (18% vs 33%, p<0.01). Patients were only included if treated at a practice offering SBRT (n=43). Notably, black patients had a significantly longer median time to treatment for the overall group and for IMRT treatment: 109 days (black) vs 97 days (white), p=0.03 and for IMRT specifically: 110 days vs. 97 days (p=0.002). However, there was no significant difference in time to treatment amongst those who received SBRT: 82 days (black) vs 99 days (white), p=0.31. CONCLUSIONS: Among patients from the SEER-Medicare dataset from 2008-2017 treated with radiation for clinically localized prostate cancer, black patients were less likely to receive SBRT and more likely to receive IMRT than white patients. Understanding racial differences in treatment patterns is important as new radiation modalities emerge to ensure equitable access and minimize disparities in prostate cancer care. Download PPT Source of Funding: Dr. Bruce Jacobs is supported in part by American Cancer Society RSG-21-045-01-CPHPS © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e1132 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Mitchell B. Alameddine More articles by this author Shan Wu More articles by this author Oluwaseun Orikogbo More articles by this author Danielle Sharbaugh More articles by this author Jonathon Yabes More articles by this author Daisy Obiora More articles by this author Michael G. Stencel More articles by this author Benjamin J. Davies More articles by this author Lindsay Sabik More articles by this author Bruce L. Jacobs More articles by this author Expand All Advertisement PDF downloadLoading ...